Literature DB >> 21570530

Impact of contrast-induced acute kidney injury definition on clinical outcomes.

Carlo Budano1, Mario Levis, Maurizio D'Amico, Tullio Usmiani, Antonella Fava, Pierluigi Sbarra, Manuel Burdese, Gian Paolo Segoloni, Antonio Colombo, Sebastiano Marra.   

Abstract

BACKGROUND: Contrast-induced acute kidney injury (CIAKI) is a frequent complication after infusion of contrast media in patients undergoing percutaneous coronary intervention. A wide range of CIAKI rates occurs after intervention between 3% and 30%, depending on the definition. The aim of this study was to identify which methodology was more effective at recognizing patients at high risk for in-hospital and out-of-hospital adverse events. METHODS AND
RESULTS: Serum creatinine increases, after contrast agent infusion, were evaluated in 755 consecutive and unselected patients. Incidences of CIAKI diagnosed by 2 common definitions varied from 6.9% (creatinine increase of ≥0.5 mg/dL, CIAKI-0.5) to 15.9% (creatinine increase of ≥25%, CIAKI-25%). Significant differences appeared between the 2 definitions of sensitivity to predict renal failure according to receiver operating characteristic curve analysis (98% for CIAKI-0.5 and 62% for CIAKI-25%), using a cutoff value of postprocedural glomerular filtration rate of 60 mL/min. Both definitions of CIAKI were related to composite adverse events, but CIAKI-0.5 showed a stronger predicting value (odds ratio 2.875 vs 1.802, P = .036). In multivariate linear regression, only CIAKI-0.5 was a predictive variable of death (odds ratio 3.174, 95% CI 1.368-7.361).
CONCLUSIONS: An increase in serum creatinine of ≥0.5 mg/dL is more sensitive because it recognizes more selectively those patients with a higher risk of mortality and morbidity. Serum creatinine increases of ≥25% overestimate CIAKI by including many patients without postprocedural relevant deterioration of renal function and affected by a lower risk of adverse events at follow-up.
Copyright © 2011 Mosby, Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21570530     DOI: 10.1016/j.ahj.2011.02.004

Source DB:  PubMed          Journal:  Am Heart J        ISSN: 0002-8703            Impact factor:   4.749


  28 in total

1.  Prevention and management of contrast-induced acute kidney injury.

Authors:  Patricia J M Best; David R Holmes
Journal:  Curr Treat Options Cardiovasc Med       Date:  2012-02

2.  Combined impact of chronic kidney disease and contrast-induced nephropathy on long-term outcomes in patients with ST-segment elevation acute myocardial infarction who undergo primary percutaneous coronary intervention.

Authors:  Hidefumi Nakahashi; Masami Kosuge; Kentaro Sakamaki; Masayoshi Kiyokuni; Toshiaki Ebina; Kiyoshi Hibi; Kengo Tsukahara; Noriaki Iwahashi; Shotaro Kuji; Mari S Oba; Satoshi Umemura; Kazuo Kimura
Journal:  Heart Vessels       Date:  2016-04-22       Impact factor: 2.037

3.  Does N-terminal pro-brain natriuretic peptide add prognostic value to the Mehran risk score for contrast-induced nephropathy and long-term outcomes after primary percutaneous coronary intervention?

Authors:  Yuan-Hui Liu; Lei Jiang; Ji-Yan Chen; Ning Tan; Yong Liu; Peng Cheng He
Journal:  Int Urol Nephrol       Date:  2016-07-29       Impact factor: 2.370

4.  The RIP1-kinase inhibitor necrostatin-1 prevents osmotic nephrosis and contrast-induced AKI in mice.

Authors:  Andreas Linkermann; Jan-Ole Heller; Agnes Prókai; Joel M Weinberg; Federica De Zen; Nina Himmerkus; Attila J Szabó; Jan H Bräsen; Ulrich Kunzendorf; Stefan Krautwald
Journal:  J Am Soc Nephrol       Date:  2013-07-05       Impact factor: 10.121

Review 5.  Strategies for Renal Protection in Cardiovascular Interventions.

Authors:  Ziad A Ali; Javier Escaned; Dariusz Dudek; Jai Radhakrishnan; Keyvan Karimi Galougahi
Journal:  Korean Circ J       Date:  2022-07       Impact factor: 3.101

6.  Derivation and validation of a risk score for contrast-induced nephropathy after cardiac catheterization in Chinese patients.

Authors:  Yu-mei Gao; Di Li; Hong Cheng; Yi-pu Chen
Journal:  Clin Exp Nephrol       Date:  2014-02-11       Impact factor: 2.801

7.  High sensitive TROponin levels In Patients with Chest pain and kidney disease: A multicenter registry - The TROPIC study.

Authors:  Flavia Ballocca; Fabrizio D'Ascenzo; Claudio Moretti; Roberto Diletti; Carlo Budano; Alberto Palazzuoli; Matthew J Reed; Tullio Palmerini; Dariusz Dudek; Alfredo Galassi; Pierluigi Omedè; Nicolas M Mieghem; David Ferenbach; Marco Pavani; Diego Della Riva; Nick L Mills; Ron T Van Domburgh; Andrea Mariani; Artur Dziewierz; Marco di Cuia; Robert Jan van Geuns; Felix Zijlstra; Serena Bergerone; Sebastiano Marra; Giuseppe Biondi Zoccai; Fiorenzo Gaita
Journal:  Cardiol J       Date:  2017-03-10       Impact factor: 2.737

8.  PET/MRI for staging patients with Hodgkin lymphoma: equivalent results with PET/CT in a prospective trial.

Authors:  M Picardi; C Cavaliere; R Della Pepa; E Nicolai; A Soricelli; C Giordano; N Pugliese; M G Rascato; I Cappuccio; G Campagna; C Cerchione; E Vigliar; G Troncone; M Mascolo; M Franzese; R Castaldo; M Salvatore; F Pane
Journal:  Ann Hematol       Date:  2021-04-28       Impact factor: 3.673

9.  Association of N-terminal pro-B-type natriuretic peptide with contrast-induced nephropathy and long-term outcomes in patients with chronic kidney disease and relative preserved left ventricular function.

Authors:  Yuan-hui Liu; Yong Liu; Ying-ling Zhou; Dan-qing Yu; Peng-cheng He; Nian-jin Xie; Hua-long Li; Ji-yan Chen; Ning Tan
Journal:  Medicine (Baltimore)       Date:  2015-04       Impact factor: 1.889

10.  Contrast-Induced Nephropathy Is Less Common in Patients with Good Coronary Collateral Circulation.

Authors:  Eyup Avci; Tarik Yildirim; Hasan Kadi
Journal:  Cardiorenal Med       Date:  2017-08-04       Impact factor: 2.041

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.